Ubs Group Ag Genenta Science S.P.A. Transaction History

Ubs Group Ag

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 13, 2025	BUY	$3.67 - $5.09 $333 - $463	91 New	91 $0
Q3 2024 Nov 14, 2024	BUY	$2.93 - $4.77 $2,839 - $4,622	969 Added 108.51%	1,862 $7,000
Q2 2024 Aug 13, 2024	BUY	$2.55 - $3.95 $2,172 - $3,365	852 Added 2078.05%	893 $2,000
Q1 2024 May 13, 2024	SELL	$3.14 - $4.84 $7,096 - $10,938	-2,260 Reduced 98.22%	41 $0
Q4 2023 Feb 09, 2024	BUY	$4.7 - $5.59 $10,814 - $12,862	2,301 New	2,301 $11,000

Q2 2023 Aug 11, 2023	BUY	$5.0 - $6.67 $3,500 - $4,669	700 New	700 $4,000
Q4 2022 Feb 08, 2023	BUY	$3.93 - $5.88 $734 - $1,099	187 Added 6.18%	3,215 $17,000
Q3 2022 Nov 10, 2022	BUY	$4.6 - $7.4 $919 - $1,480	200 Added 7.07%	3,028 $15,000
Q2 2022 Aug 10, 2022	BUY	$5.39 - $8.26 $4,662 - $7,144	865 Added 44.07%	2,828 $20,000
Q1 2022 May 16, 2022	SELL	$5.43 - $11.4 $1,086 - $2,280	-200 Reduced 9.25%	1,963 $14,000
Q4 2021 Feb 14, 2022	BUY	$10.96 - $11.87 $23,706 - $25,674	2,163 New	2,163 $24,000

555K

Ticker GNTA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 18,216,900
Market Cap $40.1M
Description
Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. The company's lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated...

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

Stay updated on Ubs Group Ag with notifications on news.